<DOC>
	<DOCNO>NCT00838890</DOCNO>
	<brief_summary>To determine safety , tolerability maximum tolerate dose BMS-63233/XL413 subject Refractory Hematologic Cancer</brief_summary>
	<brief_title>A Study BMS-863233 Patients With Hematologic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>AML current WHO diagnostic criterion , FAB type ( except APML ) , Refractory ALL , Accelerated/blast phase CML Refractory MDS total IPSS score 2 high ECOG performance status &lt; = 2 Accessible treatment , PK sample collection require study followup Total Bilirubin ≤ 1.5 x ULN ALT , AST ≤ 3 x ULN Women pregnant breastfeeding Subjects Acute Promyelocytic leukemia disease CNS leukemia disease ) Hyperleukocytosis ( define peripheral WBC &gt; 50,000/uL ) Treatment investigational agent indication within 30 day protocol enrollment Subjects history gastrointestinal disease Subjects le four week allogenic autologous stem cell transplant infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>